Although the explanation for this finding remains uncertain, it is possible that the initial introduction of SGLT2 inhibitor was associated with an improvement in HF-specific symptoms in drug-naïve T2D patients with HF. Here, SLC5A2 is linked to type 2 diabetes mellitus.